Kliniske retningslinier for udredning af cancer thyroidear 2009, udkast

Thyreoideacancer – udkast Kliniske retningslinier – revision – juni 2009
carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J.Nucl.Med. 1995;36:21-7.
153. Hall P, Holm LE, Lundell G. Second primary tumors following thyroid cancer. A Swedish recordlinkage
study. Acta Oncol. 1990;29:869-73.
154. Rubino C, de VF, Dottorini ME, Hall P, Schvartz C, Couette JE et al. Second primary malignancies in
thyroid cancer patients. Br.J.Cancer 2003;89:1638-44.
155. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies
up to three decades after the treatment of differentiated thyroid cancer. J.Clin.Endocrinol.Metab
2008;93:504-15.
156. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD et al. Second primary malignancy
risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Thyroid 2009;19:451-7.
157. Harmer CL. External beam radiotherapy for thyroid cancer. Ann.Radiol.(Paris) 1977;20:791-800.
158. Sheline GE, Galante M, Lindsay S. Radiation therapy in the control of persistent thyroid cancer.
Am.J.Roentgenol.Radium.Ther.Nucl.Med. 1966;97:923-30.
159. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thyroid
cancers. Cancer 1985;55:2062-71.
160. Farahati J, Reiners C, Stuschke M, Muller SP, Stuben G, Sauerwein W et al. Differentiated thyroid
cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage
pT4). Cancer 1996;77:172-80.
161. Saad MF, Guido JJ, Samaan NA. Radioactive iodine in the treatment of medullary carcinoma of the
thyroid. J.Clin.Endocrinol.Metab 1983;57:124-8.
162. Rasmusson B, Hansen HS. Treatment of medullary carcinoma of the thyroid. Value of calcitonin as
tumour marker. Acta Radiol.Oncol.Radiat.Phys.Biol. 1979;18:521-34.
163. Tennvall, J., Lundell, G., Wahlberg, P., and Wallin, G. Combined Doxorubicin, hyperfrationated radiotherapy
and surgery in anaplastic thyroid carcinoma. Report on three consecutive protocols. 23. 2000.
Aarhus, Denmark.
Ref Type: Conference Proceeding
164. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C et al. Prediction of disease status by
recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid
carcinoma. J.Clin.Endocrinol.Metab 2001;86:5686-90.
165. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and
follicular thyroid cancer. J.Clin.Endocrinol.Metab 2001;86:1447-63.
166. Baudin E, Do CC, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value
of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal,
in thyroid cancer patients. J.Clin.Endocrinol.Metab 2003;88:1107-11.
167. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C et al. Recombinant human thyrotropin-stimulated
serum thyroglobulin combined with neck ultrasonography has the highest sensitivity
in monitoring differentiated thyroid carcinoma. J.Clin.Endocrinol.Metab 2003;88:3668-73.
168. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA et al. Serum thyroglobulin
autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance
62